SEC Company Response from Rein Therapeutics, Inc. (RNTX) (CIK 0001420565) (RNTX) — Jun 19, 2017
Rein Therapeutics, Inc. (RNTX) (CIK 0001420565)
Date: June 19, 2017 · CIK: 0001420565 · Accession: 0001193125-17-206493
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-218474
Letter
+1 617 526 6000(t)
+1 617 526 5000(f)
wilmerhale.com
June 19, 2017
By Electronic Submission
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Suzanne Hayes
Re: Aileron Therapeutics, Inc.
Registration Statement on Form S-1
Filed June 2, 2017
File No. 333-218474
Ladies and Gentlemen:
On behalf of Aileron Therapeutics, Inc. (the “Company”) set forth below is the Company’s response to the comment of the staff (the “Staff”) of the Securities and Exchange Commission provided orally by Joseph McCann of the Staff on June 13, 2017 (the “Oral Comment”) with respect to the Company’s Registration Statement on Form S-1 (the “Registration Statement”).
This letter is being filed with Amendment No. 1 to the Registration Statement (“Amendment No. 1”). For convenience, a summary of the Oral Comment is set forth below. The Company has responded to the Oral Comment by making changes to the disclosure in the Registration Statement.
1. Please expand the discussion of the Company’s rights and obligations under the Harvard and Dana Farber Cancer Institute license agreement with respect to third party proposed products.
Response: In response to the Oral Comment, the Company has revised the disclosure on page 114 of Amendment No. 1.
Wilmer Cutler Pickering Hale and Dorr LLP, 60 State Street, Boston, Massachusetts 02109
Beijing Berlin Boston Brussels Denver Frankfurt London Los Angeles New York Palo Alto Washington
Securities and Exchange Commission
Division of Corporation Finance
June 19, 2017
Page 2
If you have any further questions or comments, or if you require any additional information, please contact the undersigned by telephone at (617) 526-6663 or facsimile at (617) 526-5000. Thank you for your assistance.
Best regards,
/s/ Stuart M. Falber
Show Raw Text
CORRESP 1 filename1.htm CORRESP +1 617 526 6000(t) +1 617 526 5000(f) wilmerhale.com June 19, 2017 By Electronic Submission Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Suzanne Hayes Re: Aileron Therapeutics, Inc. Registration Statement on Form S-1 Filed June 2, 2017 File No. 333-218474 Ladies and Gentlemen: On behalf of Aileron Therapeutics, Inc. (the “Company”) set forth below is the Company’s response to the comment of the staff (the “Staff”) of the Securities and Exchange Commission provided orally by Joseph McCann of the Staff on June 13, 2017 (the “Oral Comment”) with respect to the Company’s Registration Statement on Form S-1 (the “Registration Statement”). This letter is being filed with Amendment No. 1 to the Registration Statement (“Amendment No. 1”). For convenience, a summary of the Oral Comment is set forth below. The Company has responded to the Oral Comment by making changes to the disclosure in the Registration Statement. 1. Please expand the discussion of the Company’s rights and obligations under the Harvard and Dana Farber Cancer Institute license agreement with respect to third party proposed products. Response: In response to the Oral Comment, the Company has revised the disclosure on page 114 of Amendment No. 1. Wilmer Cutler Pickering Hale and Dorr LLP, 60 State Street, Boston, Massachusetts 02109 Beijing Berlin Boston Brussels Denver Frankfurt London Los Angeles New York Palo Alto Washington Securities and Exchange Commission Division of Corporation Finance June 19, 2017 Page 2 If you have any further questions or comments, or if you require any additional information, please contact the undersigned by telephone at (617) 526-6663 or facsimile at (617) 526-5000. Thank you for your assistance. Best regards, /s/ Stuart M. Falber Stuart M. Falber cc: Vanessa Robertson, Securities and Exchange Commission James Rosenberg, Securities and Exchange Commission Jeffrey Gabor, Securities and Exchange Commission Joseph McCann, Securities and Exchange Commission Joseph A. Yanchik III, Aileron Therapeutics, Inc. Wilmer Cutler Pickering Hale and Dorr LLP, 60 State Street, Boston, Massachusetts 02109 Beijing Berlin Boston Brussels Denver Frankfurt London Los Angeles New York Palo Alto Washington